Switching off renal inflammation by anti-inflammatory mediators: the facts, the promise and the hope.
Baud
L
L
INSERM U64, Hôpital Tenon, Paris, France. Laurent.baud@tnn.ap-hop-paris.fr
Fouqueray
B
B
Bellocq
A
A
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000378:metabolism / Q000627:therapeutic use*; D016207:Cytokines / Q000494:pharmacology / Q000502:physiology; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors* / Q000502:physiology; D053590:Interleukin 1 Receptor Antagonist Protein; D016753:Interleukin-10 / Q000494:pharmacology / Q000502:physiology; D018793:Interleukin-13 / Q000494:pharmacology / Q000502:physiology; D015847:Interleukin-4 / Q000494:pharmacology / Q000502:physiology; D018121:Receptors, Cytokine / Q000502:physiology; D012795:Sialoglycoproteins / Q000494:pharmacology / Q000502:physiology
D000893:Anti-Inflammatory Agents; D016207:Cytokines; C507763:IL1RN protein, human; D018836:Inflammation Mediators; D053590:Interleukin 1 Receptor Antagonist Protein; D018793:Interleukin-13; D018121:Receptors, Cytokine; D012795:Sialoglycoproteins; D016753:Interleukin-10; D015847:Interleukin-4